Evidence map›Paper›PMID 34014538›Full record

ArticleAdvances in experimental medicine and biology2021

The Heterogeneity Metabolism of Renal Cell Carcinomas.

Mohammadreza Zarisfi, Tu Nguyen, Jessie R Nedrow, Anne Le

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advances in experimental medicine and biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.2field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Glutamine Metabolism in Cancer.Advances in experimental medicine and biology · 2021
    Article
  3. Glucose Metabolism in Cancer: The Warburg Effect and Beyond.Advances in experimental medicine and biology · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Mohammadreza ZarisfiDepartment of Radiology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Tu NguyenUniversity of California, Los Angeles (UCLA) David Geffen School of Medicine, Los Angeles, CA, USA.
Jessie R NedrowDepartment of Radiology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Anne LeDepartment of Pathology and Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. annele@jhmi.edu.
Johns Hopkins University · USJohns Hopkins Medicine · USUniversity of California, Los Angeles · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

According to data from the American Cancer Society, cancer is one of the deadliest health problems globally. Annually, renal cell carcinoma (RCC) causes more than 100,000 deaths worldwide [1-4], posing an urgent need to develop effective treatments to increase patient survival outcomes. New therapies are expected to address a major factor contributing to cancer's resistance to standard therapies: oncogenic heterogeneity. Gene expression can vary tremendously among different types of cancers, different patients of the same tumor type, and even within individual tumors; various metabolic phenotypes can emerge, making singletherapy approaches insufficient. Novel strategies targeting the diverse metabolism of cancers aim to overcome this obstacle. Though some have yielded positive results, it remains a challenge to uncover all of the distinct metabolic profiles of RCC. In the quest to overcome this obstacle, the metabolic oriented research focusing on these cancers has offered freshly new perspectives, which are expected to contribute heavily to the development of new treatments.

Indexed as

Carcinoma, Renal CellKidney NeoplasmsHumansPhenotypeGlucose metabolismGlutamine metabolismMetabolic phenotypesOncogenic heterogeneity—intratumoral heterogeneityRenal cell carcinoma

Identifiers

PMID34014538
PMCPMC9703859
OpenAlexW3162068981

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.